| Pacific white shrimp (Litopenaeus vannamei) |
| 1 | 0, 5, 10, 20 and 30% | 50% | 84 | ↑ Weight gain (5%) | n.d. | ↑ Fillet lipid content (20%) | Inhibition of Vibrio parahaemolyticus (20%) | No significant change in THC, hemocyanin, serum protein, cholesterol | n.d. | Yildirim-Aksoy et al., 2022 |
| 2 | 0, 10, 20 and 30% | 10–20% | 49 | ↓ Growth rate (30%) | n.d. | ↓ Lipid content; ↑ CPT, SOD, IDH activities | ↑ Antioxidant enzymes | ↓ ACP, ALP, lipase (30%) | n.d. | Chen et al., 2023 a |
| 3 | 0, 1, 1.5, and 2% | n.d. | 42 | ↑ Growth, feed and protein efficiency | No significant effect | ↑ Protein retention | n.d. | n.d. | n.d. | Herawati et al., 2024 |
| 4 | 0, 25, 50, 75 and 100% | 34.92% | 56 | ↑ % weight gain (75%) | n.d. | ↑ Lauric acid; lipid-related gene expression | ↑ Immune-related gene expression | ↑ ACP, PO, NOS | n.d. | He et al., 2024 |
| 5 | n.d. | n.d. | 28 | ↓ Growth | No significant effect | n.d. | n.d. | n.d. | ↓ Digestibility of protein and dry matter | Li et al., 2022 |
| 6 | 0, 25, 50, 75 and 100% | 50% | 45 | ↑ Weight gain (25%) | ↑ Survival (25%) | ↑ Hepatosomatic index | ↑ SOD, GPx | n.d. | ↑ Protease activity (25%) | He et al., 2022 a |
| 7 | n.d. | 24% | n.d. | ↑ RGR, FCR, protein efficiency | n.d. | ↑ Amino acid and fatty acid profile | n.d. | n.d. | n.d. | Herawati et al., 2023 |
| 8 | 0, 7, 14, 21, 28 and 36% | 36% | 63 | ↓ Weight gain and SGR | n.d. | ↓ Whole-body protein and lipid | n.d. | n.d. | n.d. | Cummins et al., 2017 |
| 9 | n.d. | n.d. | 45 | n.d. | ↑ Survival | n.d. | ↑ PO, SOD, immune gene expression | n.d. | n.d. | Shin et al., 2021 |
| 10 | 0, 25, 50, 75 and 100% | 50% | 45 | n.d. | n.d. | ↑ Hepatosomatic index | ↑ SOD, GPx | n.d. | ↑ Protease activity (25%) | He et al., 2022 b |
| 11 | 0, 25, 50, 75 and 100% | 26.46% | n.d. | ↑ Growth performance | n.d. | n.d. | n.d. | n.d. | ↑ FCR | Nunes et al., 2023 |
| 12 | 0, 10, 20, and 30% | 75% | 49 | n.d. | ↑ Survival (10%) | ↓ Intestinal folds (20–30%) | ↑ AMP genes | n.d. | n.d. | Chen et al., 2021 |
| 13 | 0, 25, 50, 75 and 100% | 50% | 45 | n.d. | n.d. | n.d. | ↑ Gut microbiota diversity | n.d. | n.d. | He et al., 2024 |
| 14 | Exuviae, cocoons, imago | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ↑ Protein digestibility | Fricke et al., 2024 |
| 15 | Multi-insect meals | n.d. | 65 | ↑ Growth (BSF best) | n.d. | ↑ AA and FA content | ↑ Antioxidant enzymes | n.d. | ↑ ADC | Shin et al., 2021 |
| 16 | 0, 1 and 2% | n.d. | n.d. | ↑ Palatability | n.d. | ↑ Free AA content | n.d. | n.d. | n.d. | Terrey et al., 2021 |
| 17 | 0, 20, 40, 60, 80 and 100% | 20% | 60 | ↓ Flesh protein, collagen | n.d | ↑ PUFA, free AA | n.d. | n.d. | n.d. | Zheng et al., 2024 |
| 18 | 0, 0.5 to 5% | 50% | 90 | ↑ Growth and feed efficiency | ↑ Against V. harveyi | n.d. | ↑ THC, lysozyme | n.d. | n.d. | Novriadi et al., 2023 |
| 19 | 0, 20, 40, and 60% | n.d. | 57 | ↑ Growth (40–60%) | n.d. | n.d. | ↑ PO, SOD, GPx | n.d. | n.d. | Shin et al., 2020 |
| 20 | 0, 10, 20, 30, 40 and 50% | n.d. | 60 | ↓ Growth | n.d. | n.d. | ↑ TRAF6, TOLL1 genes | n.d. | n.d. | Chen et al., 2023 b |
| 21 | 0, 7.5, 15 and 22.5% | 22.5% | 49 | No sig. change | n.d. | ↑ Protein content | n.d. | n.d. | n.d. | Fahrur et al., 2021 |
| 22 | 0, 15, 30, 45, 60 and 80% | 60% | 56 | ↓ Growth (80%) | n.d. | ↓ Crude protein | ↑ TAC (80%) | n.d. | n.d. | Wang et al., 2021 |
| 23 | 0, 10, 15, 20, 25 and 30% | 30% | 56 | ↑ Growth and SGR (10–30%) | n.d. | ↑ Calcium (25%) | ↑ TAC, POD, CAT (20%) | n.d. | n.d. | Hu et al., 2019 |
| 24 | 0, 20, 40, 60, 80 and 100% | 80% | 56 | ↑ Growth (80%) | ↑ Survival (100%) | ↑ AST, ALT, cholesterol (100%) | ↓ GPx, SOD (100%) | n.d. | n.d. | Ming et al., 2024 |
| 25 | 0, 10, 20 and 30% | n.d. | 49 | ↓ Growth (30%) | No significant difference | ↓ Lipid, TAG, cholesterol | Gene regulation changes | n.d. | n.d. | Chen et al., 2022 |
| 26 | 0, 2, 5 and 10% | 5–10% | 45 | ↑ Weight gain | ↑ Survival | ↓ Vibrio spp. count | ↑ Immune parameters | n.d. | n.d. | Keetanon et al., 2024 |
| 27 | 0, 4.12, 8.24, 12.36, 16.48 and 20.61% | 75% | 56 | No significant effect (≤20.61%) | n.d. | ↓ Inflammation (>16.48%) | ↑ Antioxidant capacity | n.d. | n.d. | Chang et al., 2025 |
| 28 | n.d. | n.d. | 83 | ↑ Weight gain | n.d. | ↓ Protein digestibility | – | n.d. | n.d. | Candela-Maldonado et al., 2025 |
| 29 | 0, 5, 10 and 15% | n.d. | 56 | ↑ Growth | n.d. | ↑ Lauric acid | ↑ PO, LZM, GPx, immune genes | n.d. | n.d. | Ko et al., 2025 |
| 30 | 0, 25, 50, 75 and 100% | n.d. | 56 | ↑ Growth (100%) | ↑ Survival | ↑ Fatty acid content | ↑ SOD, GPx | n.d. | n.d. | Shin et al., 2025 |
| 31 | 0, 25, 50 and 100% | n.d. | 70 | ↑ Growth (50%) | n.d. | n.d. | n.d. | n.d. | ↑ Trypsin and lipase (50%) | Zamani and Jafari, 2025 |
|
| Freshwater shrimp (Macrobrachium rosenbergii) |
|
| 32 | n.d. | n.d. | 7 | ↑ Growth | n.d. | n.d. | n.d. | n.d. | n.d. | McCallum et al., 2020 |
| 33 | 0, 3 and 20% | n.d. | 60 | No negative effect | No significant effect | ↑ α-tocopherol, carotenoids | No significant change in immune genes | ↑ B cells | n.d. | Zarantoniello et al., 2023 |
| 34 | 0, 15, 30 and 45% | n.d. | 35 | ↑ Growth | ↑ Survival | n.d. | n.d. | n.d. | n.d. | Raja Hishamudin, 2020 |
| 35 | 0, 5, 10 and 15% | 50% | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ↑ Protein digestibility | Harun et al., 2021 |
| 36 | 0, 5, 10 and 15% | n.d. | n.d. | n.d. | n.d. | ↑ Protein, lipid | n.d. | n.d. | ↑ Protein digestibility | Amiruddin et al., 2021 |
|
| Freshwater crayfish |
|
| 37 | 0 and 12% | n.d. | 56 | ↑ Growth | n.d. | n.d. | ↑ Immune gene expression | ↑ THC | ↑ Lactobacillus in gut | Foysal et al., 2021 |
| 38 | n.d. | n.d. | 60 | n.d. | n.d. | ↑ Protein, energy in muscle | ↑ Immune enzymes | ↑ THC | ↑ Bacterial activity | Foysal et al., 2019 |
| 39 | n.d. | n.d. | 60 | ↑ Growth | ↑ Survival | n.d. | n.d. | n.d. | n.d. | Koca et al., 2024 |
| 40 | 0, 50 and 100% | n.d. | 98 days | ↑ Growth | ↑ Survival | ↑ FA (C16:0, C18:1, C18:2) | n.d. | n.d. | n.d. | Alvanou et al., 2023 |
| 41 | 0, 20, 40, 60, 80, and 100% | 40% | 60 days | ↑ Growth | – | – | n.d. | n.d. | n.d. | Özdoğan et al., 2024 |
| 42 | n.d. | n.d. | 56 days | ↑ Growth | n.d. | ↑ FA, EPA, DHA | ↑ SOD, PO, GPx | n.d. | ↑ Digestibility | Chu and Huang, 2024 |
| 43 | 0, 50, 100, 150 and 200 mg/kg AMP | n.d. | 56 days | ↑ Growth (100–150 mg/kg) | ↑ Resistance to A. hydrophila | n.d. | ↑ Immune enzymes and gene expression | n.d. | ↑ Gut microbiota | Zhang et al., 2024 |
| 44 | 0, 7, 14, 21 and 28% | 17.1% | 60 days | ↑ Growth (14%) | n.d. | ↓ MDA (14%) | ↑ SOD, GPx, CAT | n.d. | n.d. | Wang et al., 2022 |
| 45 | n.d. | n.d. | 28 days | No sig. growth | n.d. | n.d. | n.d. | n.d. | ↓ FCR | Subchan et al., 2024 |
| 46 | 0, 20, 40, 60, 80 and 100% | 34.25% | 90 days | ↑ Growth (40%) | n.d. | ↑ Protein (80%) | ↑ Lysozyme, SOD | n.d. | ↑ Nutrient efficiency | Han et al., 2023 |
|
| Crab |
|
|
|
|
|
|
|
|
|
|
|
| 47 | 0, 25, 50, 75 and 100% | 50% | 56 days | ↑ Growth (25–50%) | ↑ Survival 25–50%) | n.d. | ↑ ACP, ALP, LZM | n.d. | ↑ Intestinal folds | Yao et al., 2024 |
| 48 | 0, 6, 12, 18 and 24% | n.d. | n.d. | n.d. | n.d. | ↑ Ovarian lipid metabolism | n.d. | n.d. | n.d. | Qiao et al., 2025 |
| 49 | 0, 10, 20, 30, 40 and 50% | 50% | 56 days | ↓ Growth (50%) | n.d. | n.d. | ↓ Antioxidant enzymes | n.d. | n.d. | Wang et al., 2024 |
| 50 | 0, 5, 10 and 15% | 10% | 56 days | ↑ Growth (10%) | n.d. | ↑ Protein, lipid | ↑ Digestive enzyme activity | n.d. | n.d. | Yang et al., 2023 |
| 51 | 0, 25, 50 and 75% | 25–50% | 28 days | ↑ Growth (25–50%) | n.d. | ↓ PUFA (75%) | n.d. | n.d. | n.d. | Zhang et al., 2023 |
|
| Lobster |
|
| 52 | n.d. | 15% | n.d. | n.d. | n.d. | ↑ Body glycogen | n.d. | n.d. | ↑ Chitinase activity | Goncalves et al., 2024 |
| 53 | 25% | n.d. | 56 days | ↑ Growth | n.d. | ↑ MUFA, SFA, ω9 FA | n.d. | n.d. | n.d. | Saputra et al., 2024 |
| 54 | 0, 25, 35 and 50% | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ↓ Feed dry matter loss (high salinity) | Saputra and Fotedar, 2023 |
| 55 | 0, 25, 35 and 50% | 50% | 56 days | No sig. effect | n.d. | n.d. | ↑ Inflammatory cytokines (35%) | n.d. | n.d. | Saputra and Fotedar, 2024 |